GCP
NPCE icon

GSA Capital Partners’s Neuropace NPCE Stock Holding History

GSA Capital Partners’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Sell
115,535
-2,137
-2% -$34.4K 0.12% 198
2026
Q1 		$1.55M Buy
117,672
+87,751
+293% +$1.32M 0.1% 264
2025
Q4 		$462K Sell
29,921
-24,615
-45% -$329K 0.04% 874
2025
Q3 		$562K Buy
54,536
+1,323
+2% +$12.5K 0.05% 768
2025
Q2 		$593K Sell
53,213
-1,855
-3% -$23.2K 0.04% 806
2025
Q1 		$677K Sell
55,068
-1,316
-2% -$16.5K 0.06% 588
2024
Q4 		$631K Buy
+56,384
New +$490K 0.05% 728

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GSA Capital Partners's NPCE Position: Q2 2026 in Review

GSA Capital Partners reduced its Neuropace (NPCE) stake by 1.8% in Q2 2026, selling an estimated $34.4K and leaving 115,535 shares worth $1.84M. The position accounts for 0.12% of the portfolio, ranked #198.

GSA Capital Partners first reported a position in NPCE in Q4 2024 and has held it in 7 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • GSA Capital Partners held 115,535 shares of Neuropace worth $1.84M as of Q2 2026.
  • GSA Capital Partners sold 2,137 Neuropace shares in Q2 2026, an estimated $34.4K.
  • Neuropace made up 0.12% of GSA Capital Partners's portfolio in Q2 2026, its #198 holding.
  • GSA Capital Partners first reported a position in Neuropace in Q4 2024 and has held it in 7 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.